Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients

Table 3

Clinical and biochemical characteristics of the diabetic patients.

	NVD	VD
Male Sex (%)
	Average +/− SD	Average +/− SD	value
Age	56.2 +/− 2.3	60.8 +/− 1.4	0.070
BMI	31.0 +/−1.3	29.7 +/− 0.8	0.036
Total protein (g/L)	71.1 +/− 4.8	70.3 +/− 4.4	0.369
Albuminemia (g/L)	41.9 +/− 2.8	42.5 +/− 2.8	0.156
Fructosamine (mol/g)	4.68 +/− 0.78	4.84 +/− 0.77	0.392
HbA1c (%)	8.9 +/− 0.2	9.1 +/− 0.2	0.31
Glycemia (mmol/L)	9.0 +/− 2.9	9.2 +/− 3.1	0.754
Total cholesterol (mmol/L)	4.17 +/− 0.84	4.11 +/− 1.17	0.807
HDL-cholesterol (mmol/L)	1.13 +/− 0.30	1.12 +/− 0.28	0.882
LDL-cholesterol (mmol/L)	2.49 +/− 0.79	2.52 +/− 0.97	0.887
Triglycerides (mmol)	1.34 (0.99–1.77)	1.49 (0.99–1.91)	0.520
(25–75th percentile)
ApoA (mmol/L)	1.30 +/− 0.22	1.30 +/− 0.22	1.000
ApoB (mmol/L)	0.89 +/− 0.21	0.88 +/− 0.28	0.866
Urine protein (g/L)	⁡0.09 (0.06–0.13)	0.10 (0.07–0.16)	0.370
(25–75th percentile)
Microalbuminuria (mg/L)	63.1 +/− 153.2	83.5 +/− 192.5	0.606

The panel of diabetic patients is divided into two groups: diabetic patients with and without vascular disease (resp., VD, , and NVD, ).